ArticleCancers2021

Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models.

Cristina Meregalli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.